<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855565</url>
  </required_header>
  <id_info>
    <org_study_id>ALY688-SR-101</org_study_id>
    <nct_id>NCT04855565</nct_id>
  </id_info>
  <brief_title>ALY688-SR in Generally Healthy Overweight or Obese Adults</brief_title>
  <official_title>Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of ALY688-SR in Generally Healthy Overweight or Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allysta Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research Australia Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Allysta Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study of ALY688-SR administered as a subcutaneous injection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      single ascending doses of ALY688-SR compared to placebo administered as a subcutaneous&#xD;
      injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit due to COVID-19 pandemic restrictions&#xD;
  </why_stopped>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Site staff treating subjects, subjects themselves and the Investigator will be blinded to the treatments being administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change between pre- and post-intervention safety and tolerability assessments</measure>
    <time_frame>baseline, pre-intervention through study completion at 16 days</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by lab evaluations, ECG, vital signs and physical examinations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>ALY688-SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo for ALY688-SR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALY688-SR</intervention_name>
    <description>single dose subcutaneous injection</description>
    <arm_group_label>ALY688-SR</arm_group_label>
    <arm_group_label>Matching placebo for ALY688-SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index 24 to 35 kg/m2 Body weight 60 to 120 kg,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed diabetes on treatment Inadequately managed hypertension Poorly controlled&#xD;
             hypercholesterolemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Snyder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

